[
    [
        {
            "time": "2021-11-01",
            "original_text": "Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan",
            "features": {
                "keywords": [
                    "Dicerna",
                    "Novo Nordisk",
                    "Takeover",
                    "Acquisition",
                    "$3.3 Billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firm",
            "features": {
                "keywords": [
                    "Investigation",
                    "Sale",
                    "DRNA",
                    "Investors"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "legal",
                    "investor relations"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firm",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "RNAi firm Dicerna Pharmaceuticals to be acquired for $3.3B",
            "features": {
                "keywords": [
                    "RNAi",
                    "Dicerna Pharmaceuticals",
                    "Acquisition",
                    "$3.3B"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "RNAi firm Dicerna Pharmaceuticals to be acquired for $3.3B",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today",
            "features": {
                "keywords": [
                    "Dicerna Pharmaceuticals",
                    "Rocketing",
                    "Higher"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today",
            "features": {
                "keywords": [
                    "DRNA",
                    "Novo Nordisk",
                    "Deal",
                    "Skyrocketing"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion",
            "features": {
                "keywords": [
                    "Dicerna",
                    "Novo Nordisk",
                    "Buy",
                    "Research Partner",
                    "$3.3 Billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Dicerna",
                    "Buyout",
                    "$3.3B"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Eli Lilly",
                    "Pfizer",
                    "Novo Nordisk"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "UPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
            "features": {
                "keywords": [
                    "Denmark",
                    "Novo Nordisk",
                    "Dicerna Pharma",
                    "$3.3 billion"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "UPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Novo Nordisk strikes $3.3 billion deal to buy research partner Dicerna Pharmaceuticals",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Deal",
                    "Research Partner",
                    "Dicerna Pharmaceuticals",
                    "$3.3 billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk strikes $3.3 billion deal to buy research partner Dicerna Pharmaceuticals",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
            "features": {
                "keywords": [
                    "Denmark",
                    "Novo Nordisk",
                    "Dicerna Pharma",
                    "$3.3 billion"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Novo Nordisk to Acquire Dicerna Pharmaceuticals in $3.3B Deal",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Acquire",
                    "Dicerna Pharmaceuticals",
                    "$3.3B"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk to Acquire Dicerna Pharmaceuticals in $3.3B Deal",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Novo Nordisk Agrees to Buy Dicerna Pharma for $3.3 Billion",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Agrees",
                    "Buy",
                    "Dicerna Pharma",
                    "$3.3 Billion"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Agrees to Buy Dicerna Pharma for $3.3 Billion",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]